174
Participants
Start Date
December 7, 2022
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
RP903
Ia:RP903 50mg, 100mg, 200mg, 300mg,350mg,or other dose, po qd for each 28-day cycle； Ib: RP903,RP2D,po qd for each 28-day cycle
RECRUITING
Beijing Cancer Hospital, Beijing
RECRUITING
The First Affiliated Hospital of Bengbu Medical College, Bengbu
RECRUITING
Jilin Cancer Hospital, Changchun
RECRUITING
Jilin University First Hospital, Changchun
RECRUITING
Sichuan Cancer Hospital, Chengdu
RECRUITING
Chongqing University Cancer Hospital, Chongqing
RECRUITING
Fujian Cancer Hospital, Fuzhou
RECRUITING
Fujian Medical University Union Hospital, Fuzhou
RECRUITING
Sir Run Run Shaw Hospital, Hangzhou
RECRUITING
Zhejiang Cancer Hospital, Hangzhou
RECRUITING
Harbin Medical University Cancer Hospital, Harbin
RECRUITING
Shandong Cancer Hospital & Institute, Jinan
RECRUITING
Affiliated Hospital of Jining Medical College, Jining
RECRUITING
Linyi Cancer Hospital, Linyi
RECRUITING
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang
RECRUITING
Guangxi Medical University Cancer Hospital, Nanning
RECRUITING
The Affiliated Hospital of Qingdao University, Qingdao
RECRUITING
Affiliated Cancer Hospital of Fudan University, Shanghai
RECRUITING
Liaoning Cancer Hospital&Institute, Shenyang
RECRUITING
Suining Central Hospital, Suining
RECRUITING
Hubei Cancer Hospital, Wuhan
RECRUITING
Ceneral Hosipital of Ningxia Medical University, Yinchuan
RECRUITING
Henan Cancer Hospital, Zhengzhou
Risen (Suzhou) Pharma Tech Co., Ltd.
INDUSTRY